Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy

Hweixian Leong Penny, Kelly Hainline, Nathaniel Theoharis, Bin Wu, Christian Brandl, Christian Webhofer, Mason McComb, Sabine Wittemer-Rump, Gökben Koca, Sabine Stienen, Ralf C. Bargou, Horst-Dieter Hummel, Wolfgang Loidl, Carsten Grüllich, Tobias Eggert, Ben Tran, Daniel T. Mytych

Open source

DOI: 10.3389/fimmu.2023.1261070
Published: 2023-10-23
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2023.1261070,
  title = {Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy},
  author = {Hweixian Leong Penny and Kelly Hainline and Nathaniel Theoharis and Bin Wu and Christian Brandl and Christian Webhofer and Mason McComb and Sabine Wittemer-Rump and Gökben Koca and Sabine Stienen and Ralf C. Bargou and Horst-Dieter Hummel and Wolfgang Loidl and Carsten Grüllich and Tobias Eggert and Ben Tran and Daniel T. Mytych},
  year = {2023},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2023.1261070},
  url = {https://doi.org/10.3389/fimmu.2023.1261070}
}

RIS

TY  - JOUR
TI  - Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy
AU  - Hweixian Leong Penny
AU  - Kelly Hainline
AU  - Nathaniel Theoharis
AU  - Bin Wu
AU  - Christian Brandl
AU  - Christian Webhofer
AU  - Mason McComb
AU  - Sabine Wittemer-Rump
AU  - Gökben Koca
AU  - Sabine Stienen
AU  - Ralf C. Bargou
AU  - Horst-Dieter Hummel
AU  - Wolfgang Loidl
AU  - Carsten Grüllich
AU  - Tobias Eggert
AU  - Ben Tran
AU  - Daniel T. Mytych
PY  - 2023
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2023.1261070
UR  - https://doi.org/10.3389/fimmu.2023.1261070
ER  -

APA

Penny, H. L., Hainline, K., Theoharis, N., Wu, B., Brandl, C., Webhofer, C., McComb, M., Wittemer-Rump, S., Koca, G., Stienen, S., Bargou, R. C., Hummel, H., Loidl, W., Grüllich, C., Eggert, T., Tran, B., & Mytych, D. T. (2023). Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1261070

Source records

crossref · retrieved 2026-09-26T07:27:01.347Z